Acumen Pharmaceuticals, Inc. cotiza a 2.02 USD y tiene una capitalización bursátil de $146M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta ol…
| Periodo | 2026-08 | 2026-05 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | $-0.45 | $-0.33 | $-0.41 | $-0.44 |
| Estimado | $-0.41 | $-0.46 | $-0.56 | $-0.68 |
| Sorpresa | -9.8% | +28.3% | +26.8% | +35.3% |
| Métrica | ABOS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -172.3% | -40.4% | -131.9% |
| ROA | -98.8% | -32.0% | -66.8% |
| Current Ratio | 4.07 | 2.84 | +1.23 |
| Debt / Equity | 0.32 | 0.28 | +0.04 |